Servicio de Medicina Interna, Hospital Universitario de La Princesa, Madrid, España.
Servicio de Medicina Interna, Hospital Carlos III, Madrid, España.
Med Clin (Barc). 2018 Jul 13;151(1):8-15. doi: 10.1016/j.medcli.2017.07.025. Epub 2017 Oct 6.
To evaluate the adherence to the recommendations in clinical practice performed by the Therapeutic Positioning Report (TPR) of the Spanish Agency of Medicines and Sanitary Products about the treatment with oral anticoagulants in patients aged≥75 years old with nonvalvular atrial fibrillation (NVAF) treated in Internal Medicine departments in Spain.
Observational, cross-sectional and multicenter study in which 837 patients aged≥75 years old with NVAF, with stable treatment with oral anticoagulants at least 3 months before inclusion, and that had started treatment with oral anticoagulants before the inclusion period were included.
Mean age was 83.0±5.0 years old, mean CHADS score 3.2±1.2, mean CHADS-VASc score 5.0±1.4, and mean HAS-BLED score 2.1±0.9. A percentage of 70.8 of patients were treated with vitamin K antagonists (VKA) and the rest of patients with direct oral anticoagulants (DOACs). A percentage of 65.6 of patients treated with VKA did not follow the recommendations made by the TPR compared with 43.0% of patients treated with DOACs (P<.0001). In the case of VKA, the main reason for being considered as not appropriate according to the TPR was having poor control of anticoagulation and not switching to DOACs, whereas in the case of DOACs, it was not receiving the adequate dose according to the TPR.
In a high proportion of anticoagulated elderly patients with NVAF in Spain, the recommendations performed by the TPR are not followed, particularly with VKA, since patients are not switched to DOACs despite time in therapeutic range.
评估西班牙药品和医疗产品管理局关于非瓣膜性心房颤动(NVAF)治疗的治疗定位报告(TPR)中关于≥75 岁老年患者口服抗凝剂治疗的建议在西班牙内科部门的临床实践中的遵循情况。
这是一项观察性、横断面和多中心研究,共纳入 837 名≥75 岁、NVAF 稳定、至少在纳入前 3 个月开始口服抗凝治疗且在纳入期前开始口服抗凝治疗的患者。
平均年龄为 83.0±5.0 岁,平均 CHADS 评分为 3.2±1.2,平均 CHADS-VASc 评分为 5.0±1.4,平均 HAS-BLED 评分为 2.1±0.9。70.8%的患者接受维生素 K 拮抗剂(VKA)治疗,其余患者接受直接口服抗凝剂(DOACs)治疗。与接受 DOACs 治疗的患者(43.0%)相比,接受 VKA 治疗的患者中,有 65.6%的患者未遵循 TPR 提出的建议(P<.0001)。在 VKA 组中,根据 TPR 认为不合适的主要原因是抗凝控制不佳且未转换为 DOACs,而在 DOACs 组中,原因是未根据 TPR 给予适当剂量。
在西班牙接受 NVAF 治疗的老年抗凝患者中,很大一部分患者未遵循 TPR 提出的建议,尤其是 VKA 组,尽管患者的治疗范围符合要求,但并未转换为 DOACs。